Search Results

Nicola Smith, Molecular Pharmacologist, lab head, and senior lecturer at UNSW Sydney.

In this podcast episode , Alessandro Nicoli shares how becoming the first PhD student in a new lab shaped —Alessandro Nicoli Delegating Is a Process Learning to delegate was not easy. —Alessandro Nicoli He discovered that investing time in people pays off. —Alessandro Nicoli This two-way growth has turned mentoring into one of his favorite parts of PhD life

Alessandro Nicoli’s wasn’t. —Alessandro Nicoli This perspective changed everything. —Alessandro Nicoli After graduation, a serendipitous email from Prof. —Alessandro Nicoli Want to explore computational GPCR science yourself?

👉 Strong biotech startups do not fail because the science is weak or the team is incapable. They fail when the pressure of fundraising slowly starts reshaping how decisions are made , long before anyone notices that strategy has begun to drift. In early-stage biotech, fundraising rarely feels like a strategic threat. It feels like a necessary distraction. Founders tell themselves that certain compromises are temporary, that clarity will return after the round closes. 👉 What actually happens is more subtle. Urgency replaces direction, and short-term signaling begins to outweigh long-term thinking. This is where most biotech startup fundraising mistakes are born, not from lack of intelligence or discipline, but from the belief that fundraising decisions exist outside the core strategy. 👉 In reality, every fundraising-driven adjustment leaves a structural mark on how the company operates, prioritizes, and allocates attention. Over time, these small shifts accumulate. Milestones are chosen for narrative strength rather than strategic leverage. Hiring decisions are pulled forward to support a story. Hard tradeoffs are delayed instead of resolved. 👉 None of these moves looks fatal on their own, yet together they quietly weaken even strong biotech startups. ✅ This post explores why fundraising mistakes have such a disproportionate impact on biotech companies, how these patterns emerge in otherwise well-run teams, and what founders can do to keep fundraising from taking control of their strategy. 👉 If you are preparing to raise, currently fundraising, or reflecting on a recent round, this is an opportunity to recognize where pressure may already be shaping decisions more than strategy should. Fundraising rarely breaks biotech startups overnight. It quietly reshapes decisions, long before the damage becomes visible. Fundraising turns strategy into reaction 👉 Fundraising rarely enters a biotech startup as a strategic decision-making framework. It enters as pressure. Pressure to show progress. Pressure to justify valuation. Pressure to appear confident about the future. And under pressure, even strong teams begin to confuse movement with direction. 👉 In early-stage biotech, this confusion is especially dangerous. Scientific progress already moves slowly, uncertainty is unavoidable, and timelines stretch far beyond what most investors are comfortable with. 👉 When fundraising begins, founders often respond by accelerating visible activity rather than strengthening underlying strategy. This is where one of the most common biotech startup fundraising mistakes takes root. Decisions stop being evaluated based on long-term leverage and start being filtered through a single question. Will this help the raise? 👉 When that question becomes dominant, strategy quietly shifts from intentional design to reactive justification. Teams begin to prioritize what can be explained easily over what actually matters most. Milestones are selected for narrative clarity rather than strategic necessity. Roadmaps bend toward what sounds fundable instead of what creates durable value. 👉 Over time, the company becomes highly responsive but increasingly misaligned. What makes this pattern so hard to catch is that it feels productive. Meetings increase. Slides improve. Activity intensifies. Yet clarity erodes, because reaction has replaced deliberate choice.   👉 Strong biotech startups do not fail at this stage because they stopped working hard. They fail because they stopped deciding with purpose. How biotech startup fundraising mistakes actually show up 👉 Fundraising mistakes rarely appear as obvious errors. In strong biotech startups, they surface as reasonable adjustments that seem aligned with reality. This is what makes them so difficult to recognize while they are happening. 👉 Under fundraising pressure, decision-making slowly shifts. Founders do not deliberately abandon strategy. Instead, they begin to evaluate choices through a narrower lens. What helps the raise starts to matter more than what strengthens the company. 👉 In practice, biotech startup fundraising mistakes most often show up as the following patterns: Milestones are chosen for narrative clarity rather than strategic leverage.   Experiments are prioritized because they fit a clean story, not because they meaningfully reduce scientific or commercial risk. Hiring decisions are accelerated to signal momentum.   Roles are added to demonstrate scale, even when the organization is not structurally ready to support them. Scientific priorities are reshaped to meet investor expectations.   Programs move forward because they sound fundable, not because the data justifies the timing. Hard strategic tradeoffs are postponed.   Founders delay narrowing focus, hoping clarity will emerge after the round instead of designing it upfront. Internal alignment weakens beneath visible progress.   Teams execute faster but understand less clearly why certain priorities exist, creating silent friction. 👉 Each of these decisions can be defended in isolation. The damage comes from their cumulative effect , when short-term fundraising logic quietly replaces deliberate strategy. 👉 This is why strong biotech startups often appear busiest right before they lose momentum. Activity increases, but clarity erodes , and the company becomes reactive instead of intentional. Clarity does not follow funding. Funding follows clarity. Why fundraising mistakes reshape the company before anyone notices Most biotech founders assume that fundraising mistakes show up as visible failures. A missed round. A rejected pitch. A broken investor process. In reality, the most damaging mistakes rarely appear at the surface. 👉 They take shape much earlier, inside the logic of everyday decisions, long before fundraising outcomes are known. Fundraising introduces a specific kind of cognitive pressure. It rewards confidence over uncertainty, clarity over complexity, and momentum over reflection. Under these conditions, decision making begins to shift subtly. Choices that simplify the story are favored over choices that preserve strategic truth. Decisions that reduce tension are prioritized over decisions that resolve it. 👉 The company does not become careless. It becomes selectively blind. As this pattern repeats, the organization adapts. Teams learn which questions are welcomed and which ones slow things down. Scientific nuance starts to feel inconvenient. Strategic debate is compressed into slide-friendly conclusions. 👉 What looks like alignment is often just the absence of friction, and friction disappears not because issues are solved, but because they are avoided. This is how biotech startup fundraising mistakes embed themselves into the operating system of the company. They are not single wrong calls, but accumulated shifts in how decisions are framed and justified. By the time founders sense that something feels off, the logic has already normalized. 👉 The company is still moving, still executing, but no longer questioning the direction with the same rigor. This is why strong biotech startups can lose their strategic center without any dramatic turning point. Nothing breaks all at once. Instead, clarity erodes quietly, decision by decision, under the assumption that everything will be fixed after the round closes. What actually prevents fundraising mistakes from taking over Most biotech founders try to solve fundraising-related problems by improving execution. Better decks. Clearer narratives. Tighter timelines. 👉 What they often miss is that execution quality does not protect strategy when the decision logic itself is unstable. The companies that avoid destructive fundraising mistakes do not do so because they raise faster or pitch better. They do it because they anchor fundraising inside a stronger strategic structure. 👉 That structure usually rests on a small number of non-negotiable principles. 1️⃣ They define strategic truth before investor truth. 👉 High-performing biotech teams are explicit about what must be true for the company to succeed, independent of how attractive that story sounds externally. Fundraising adapts to this reality, not the other way around. 2️⃣ They separate progress from presentation. 👉 These teams distinguish clearly between work that advances the company and work that merely explains it. Investor readiness never becomes the primary filter for scientific or organizational decisions. 3️⃣ They make hard tradeoffs early and visibly. 👉 Instead of postponing narrowing decisions until after a round, they resolve them upfront. This reduces internal ambiguity and prevents fundraising pressure from reopening questions that were already strategically settled. 4️⃣ They protect decision quality under pressure. 👉 As fundraising intensity increases, they slow down decision-making rather than accelerate it. Additional scrutiny is applied exactly where urgency would normally shortcut thinking. What unites these behaviors is not discipline for its own sake, but intent. Fundraising remains a tool, not a steering mechanism.  Strategy continues to shape decisions even when external pressure rises. ✅ This is the point where biotech startup fundraising mistakes stop accumulating. Not because risk disappears, but because decisions remain grounded in a framework that fundraising cannot easily distort. Strategic Takeaway 👉 Strong biotech startups are rarely destroyed by a single bad fundraising decision. They lose their edge when fundraising quietly becomes the logic behind everyday choices , replacing strategy with serving it. 👉 The difference between companies that survive fundraising pressure and those that drift is not discipline or ambition. It is whether decision-making remains anchored in a clear strategic framework before, during, and after the raise . Fundraising should amplify direction, not define it. When strategy leads, and fundraising follows, capital becomes leverage. When fundraising leads and strategy reacts, even strong biotech startups slowly lose coherence. ✅ The real work is not raising better. The real work is deciding clearly before pressure decides for you. Ready to Break Your Bottlenecks? If you're feeling the friction, indecision, misalignment, or slow momentum, it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough trade-offs, or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start building the mindset your company actually needs.

Nicole (Nicki) Perry-Hauser is now available What a fun chat! 📹Would you like to see the video?

GPCR Podcast, we sit down with Alessandro Nicoli, from the Technical University of Munich, to discuss

For Alessandro Nicoli, it’s an opportunity. —Alessandro Nicoli For the first time, researchers had a reliable set of predicted structures to work —Alessandro Nicoli A New Era of GPCR Research AlphaFold didn’t just fill a gap—it shifted the focus of —Alessandro Nicoli The result?

article Extracellular signal-regulated kinases – a potential pathway for GPCR-targeted drug discovery Nicola

Nicholas Holliday and how he has combined his university role with his leadership of Excellerate Bioscience

study on Multiplexed mapping of the interactome of GPCRs with receptor activity-modifying proteins Nicholas

.; Nicolas, L.; Tinel, N.; Boisseau, C.; Yverneau, P.; Charrier-Savournin, F.; Fink, M.; Trinquet, E.

Stuart Maudsley, Nicole Perry-Hauser, Lauren Slosky, Cesare Orlandi, and Simone Prömel.

Nichola J Smith's investigation: Gene expression of TAS1R taste receptors for cardiometabolic disease

studies have also reported GPR84 involvement in pain, atherosclerosis, and even metabolic disorders (Nicol

Nicole Perry-Hauser, on her selection as a 2024 Discovery Science Emerging Scholar at Vanderbilt University

GPCR Podcast, is filled with such moments, from bombing her first high school chemistry test to co-founding

Brian Krumm and Bryan Roth studied CryoEM structures of adhesion in GPCR CD97, filling gaps. For those who joined any of our symposium sessions, we kindly request a moment of your time to fill out Adhesion GPCRs CryoEM structures of adhesion in GPCR CD97: Filling in some of the gaps GPCR Activation

Take 2 minutes to fill out this survey and let us know what you liked, what you didn’t, and what we can GPCR University have been filled! Thank you for the overwhelming response. Please fill out the waitlist form. We'll let you know if any spots become available. Dr.

3 out of the 25 spots have been filled! Team Registrations are also available! To begin, please fill out this form!

In this context, mutagenesis has emerged as an "old-school" but essential technology to fill these knowledge cryo-electron microscopy have deepened our understanding of ligand-receptor interactions, mutagenesis fills

Our findings fill a gap in the understanding of CB1 allosteric regulation and could guide the rational

session in breakout rooms on Zoom; if you are interested in sharing your work with our community, kindly fill Additionally, if you participated in our Symposia in 2023, please take a moment to fill out this survey

17 out of the 25 spots have been filled! Team Registrations are also available!  Fill out this form to get started!

session in breakout rooms on Zoom; if you are interested in sharing your work with our community, kindly fill Additionally, if you participated in our Symposia in 2023, please take a moment to fill out this survey

Taken together, our study fills the missing information of GPCR/G-protein engagement and provides a framework

If you're looking to hire, fill out this form. If you want to be hired, fill out this form.

11 out of the 25 spots have been filled! Team Registrations are also available! To begin, please fill out this form!

session in breakout rooms on Zoom; if you are interested in sharing your work with our community, kindly fill Additionally, if you participated in our Symposia in 2023, please take a moment to fill out this survey

My experience has been no different, filled with valuable lessons that I hope will inspire and guide

available high-affinity radioligands, but with the development of potent fluorescent probes, this gap can filled Soave M, Briddon SJ, Hill SJ, Stoddart LA. Stoddart LA, Kilpatrick LE, Briddon SJ, Hill SJ.